. 2015 Aug 20;6(1):150–156. doi: 10.1515/tnsci-2015-0014

Table 1.

Characteristics of included studies.

Study	Pt No.	Mean age (years)	Sex (M)	Country	Intervention	Clinical outcomes	Baseline tHcy (Vit-B vs Placebo)	Follow-up time
Almeida (2010)	273	63	68%	Australia	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy Stroke recurrence	11.7 ± 1.5 vs 11.1 ± 1.3	7 years
Arshi (2015)	1773	65.9	61%	U.S.A.	2.5mg folate 0.4 mg B₁₂ 25 mg B₆	Stroke recurrence Combined incidence	NA	2 years
Dusitanond (2005)	285	NA	NA	Australia	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy	NA	6 months
Gommans (2013)	925	62.6	64%	New Zealand	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy	10 ± 3.2 vs 10 ± 3.5	3.4 years
Group VTS (2010)	1205	62.6	64%	Australia	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy Stroke recurrence Combined incidence	14.4 ± 9.2 vs 14.2 ± 7.7	3.4 years
Hankey (2004)	250	NA	NA	Australia	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy	13.4 ± 8.5 vs 12.8 ± 5.1	6 months
Hankey (2005)	285	65.3	65%	Australia	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy	13.4 ± 8.5 vs 12.8 ± 5.1	6 months
Hankey (2012)	1463	62	64%	Australia	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy Stroke recurrence Combined incidence	13.7 ± 6.6 vs 13.4 ± 4.9	3.4 years
Hankey (2013)	579	63	65%	Australia	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy	NA	6 months
Ho (2006)	336	62	65%	Singapore	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy	13.7 ± 4.4 vs 14 ± 5.2	1 year
Potter (2009)	28	70	78%	Australia	2 mg folate, 0.5 mg B₁₂, 25 mg B₆	tHcy	NA	4 years
Xia (2014)	72	68	61%	China	Folate (5 mg daily), B₁₂(0.5 mg twice daily)	tHcy	26.8 ± 9.5 vs 25.9 ± 10.9	3 months